Centessa Pharmaceuticals plc financial data

Symbol
CNTA on Nasdaq
Industry
Pharmaceutical Preparations
Location
3 Rd Floor, 1 Ashley Road, Altrincham, Cheshire, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Former names
Centessa Pharmaceuticals Ltd (to 5/24/2021)
Latest financial report
10-K - Q4 2024 - Mar 24, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.26K % +25.6%
Debt-to-equity 36.4 % -17.3%
Return On Equity -67.2 % -18.5%
Return On Assets -49.3 % -25.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 133M shares +32.8%
Common Stock, Shares, Outstanding 133M shares +34.3%
Entity Public Float 622M USD +100%
Common Stock, Value, Issued 359K USD +31.5%
Weighted Average Number of Shares Outstanding, Basic 114M shares +19%
Weighted Average Number of Shares Outstanding, Diluted 114M shares +19%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 50.8M USD -5.43%
Operating Income (Loss) -201M USD -17.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -233M USD -32.2%
Income Tax Expense (Benefit) 2.84M USD -8.22%
Net Income (Loss) Attributable to Parent -236M USD -56%
Earnings Per Share, Basic -2.06 USD/shares -31.2%
Earnings Per Share, Diluted -2.06 USD/shares -31.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 383M USD +199%
Other Assets, Current 1.78M USD +9.93%
Assets, Current 536M USD +70.2%
Deferred Income Tax Assets, Net 26.6M USD -10.3%
Property, Plant and Equipment, Net 744K USD -28.4%
Operating Lease, Right-of-Use Asset 11M USD -7.56%
Other Assets, Noncurrent 2.05M USD -19.9%
Assets 577M USD +60.1%
Accounts Payable, Current 7.14M USD -39.5%
Employee-related Liabilities, Current 9.47M USD +40.6%
Accrued Liabilities, Current 50.9M USD +84.5%
Liabilities, Current 58M USD +47.3%
Operating Lease, Liability, Noncurrent 8.29M USD -6.77%
Other Liabilities, Noncurrent 29K USD 0%
Liabilities 175M USD +41.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 4.21M USD +182%
Retained Earnings (Accumulated Deficit) -989M USD -31.3%
Stockholders' Equity Attributable to Parent 402M USD +70%
Liabilities and Equity 577M USD +60.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.3M USD +22.1%
Net Cash Provided by (Used in) Financing Activities 10.5M USD
Net Cash Provided by (Used in) Investing Activities 16.8M USD
Common Stock, Shares Authorized 184M shares 0%
Common Stock, Shares, Issued 133M shares +34.3%
Common Stock, Par or Stated Value Per Share 0 GBP/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.81M USD +92.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 383M USD +199%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.53M USD +7.89%
Deferred Tax Assets, Valuation Allowance 94.9M USD +29.6%
Deferred Tax Assets, Gross 124M USD +17.6%
Operating Lease, Liability 8.89M USD -5.38%
Depreciation 86K USD +132%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -233M USD -57.4%
Lessee, Operating Lease, Liability, to be Paid 14M USD -10.2%
Property, Plant and Equipment, Gross 1.54M USD +2.27%
Operating Lease, Liability, Current 602K USD +19.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.67M USD +2.02%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.63M USD +2%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Deferred Income Tax Expense (Benefit) 434K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.14M USD -17.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.7M USD +1.98%
Deferred Tax Assets, Operating Loss Carryforwards 96.4M USD +24.5%
Unrecognized Tax Benefits 2.61M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.73M USD +2%
Operating Lease, Payments 400K USD
Additional Paid in Capital 1.39B USD +40.3%
Depreciation, Depletion and Amortization 240K USD +170%
Deferred Tax Assets, Net of Valuation Allowance 29.3M USD -9.52%
Share-based Payment Arrangement, Expense 33.5M USD +14.1%
Interest Expense 10.1M USD +24.2%